BerGenBio
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including cancer and severe respiratory infections. AXL: a promising target to treat life-threatening diseases The tyrosine kinase target AXL is known to play an important role in both the innate and adaptive immune systems, BerGenBio is developing two highly selective AXL inhibitors bemcentinib and tilvestamab. Business model: R&D excellence and strategic partnerships BerGenBio is leveraging its solid leadership position in understanding the role of AXL and related kinase signalling in diseases of high unmet need to develop a diversified pipeline of selective AXL inhibitors.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for BerGenBio.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-05 16:49 |
Share Issue/Capital Change
BerGenBio ASA - Updated key information related to the rights issue
|
English | 10.0 KB | |
| 2025-08-04 13:40 |
Post-Annual General Meeting Information
BerGenBio ASA: Approval of the merger plan and the fully underwritten rights is…
|
Norwegian | 794.1 KB | |
| 2025-08-04 13:40 |
M&A Activity
BerGenBio ASA: Approval of the merger plan and the fully underwritten rights is…
|
English | 2.2 KB | |
| 2025-07-03 14:53 |
Pre-Annual General Meeting Information
BerGenBio ASA: Notice of Extraordinary General Meeting - Attachment: BerGenBio_…
|
Norwegian | 441.1 KB | |
| 2025-07-03 14:53 |
Pre-Annual General Meeting Information
BerGenBio ASA: Notice of Extraordinary General Meeting
|
English | 2.6 KB | |
| 2025-06-30 22:30 |
Share Issue/Capital Change
BerGenBio ASA - Key information related to the rights issue
|
English | 10.0 KB | |
| 2025-06-30 22:05 |
Share Issue/Capital Change
Announcement of fully underwritten rights issue - Attachment: Attachment_overvi…
|
English | 101.2 KB | |
| 2025-06-30 22:05 |
Share Issue/Capital Change
Announcement of fully underwritten rights issue
|
English | 21.0 KB | |
| 2025-06-30 22:00 |
M&A Activity
BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer ther…
|
English | 19.5 KB | |
| 2025-06-26 11:29 |
Post-Annual General Meeting Information
BerGenBio ASA - Minutes from the annual general meeting 2025 - Attachment: BerG…
|
Norwegian | 419.9 KB | |
| 2025-06-26 11:29 |
Post-Annual General Meeting Information
BerGenBio ASA - Minutes from the annual general meeting 2025
|
English | 1.1 KB | |
| 2025-06-03 19:22 |
M&A Activity
BerGenBio ASA: Update on Strategic Review Process and Status of Activities
|
English | 2.6 KB | |
| 2025-06-03 15:55 |
Pre-Annual General Meeting Information
BerGenBio ASA: Notice of Annual General Meeting - Attachment: Notice_of_AGM_Ber…
|
Norwegian | 424.8 KB | |
| 2025-06-03 15:55 |
Pre-Annual General Meeting Information
BerGenBio ASA: Notice of Annual General Meeting
|
English | 2.6 KB | |
| 2025-04-30 07:51 |
Report Publication Announcement
Financial calendar
|
English | 666 bytes |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Lytix Biopharma AS | Norway | LYTIX | |
|
MaaT Pharma | France | MAAT | |
|
Mabion S.A. | Poland | MAB | |
|
Marinomed Biotech AG | Austria | MARI | |
|
Matricelf Ltd. | Israel | MTLF | |
|
MDxHealth SA | Belgium | MDXH | |
|
Medesis Pharma S.A. | France | ALMDP | |
|
Medica | Italy | MDC | |
|
Medicofarma Biotech Spolka Akcyjna | Poland | MDB | |
|
Medigene AG | Germany | MDG1 |